Asthma Therapeutics Market by Product (Inhalers, Nebulizers), Drug Class (Anti-Inflammatory, Bronchodilators, Combination Therapy), Route of administration - Global Forecast 2024-2030

Asthma Therapeutics Market by Product (Inhalers, Nebulizers), Drug Class (Anti-Inflammatory, Bronchodilators, Combination Therapy), Route of administration - Global Forecast 2024-2030

The Asthma Therapeutics Market size was estimated at USD 24.70 billion in 2023 and expected to reach USD 27.26 billion in 2024, at a CAGR 10.63% to reach USD 50.10 billion by 2030.

The asthma therapeutics market encompasses all activities related to the research, development, production, and distribution of medications and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory disorder. This market serves a diverse population of patients across age groups who require either maintenance therapy or acute care for asthmatic episodes. The market scope includes various therapeutic products such as anti-inflammatory drugs, bronchodilators, combination therapies, biologics, and delivery devices such as inhalers and nebulizers. The primary applications within the asthma therapeutics market include long-term control medicines, which aim to maintain a stable condition, and quick-relief treatments for sudden symptoms. End-users of these products typically entail individuals diagnosed with asthma, healthcare professionals like pulmonologists, and healthcare settings, including hospitals, clinics, and homecare environments. The scope extends to support services like patient education and training on the proper use of asthma management devices. The need for asthma therapeutics is increasing due to growing incidences of asthma and other respiratory diseases, recent improvements in allergy detection and diagnostic technologies, and extensive demand for monoclonal antibodies. However, the asthma therapeutics market faces certain challenges, including limitations and side effects of asthma therapeutic devices, high costs associated with advanced treatments, and limited therapeutic reach in remote and rural areas. On the other hand, several opportunities are emerging within the asthma therapeutics market, including the development of combination therapeutics for the treatment and extensive research and development (R&D) efforts for asthma treatment. There is also an increasing trend towards digital health solutions, such as smart inhalers that can track usage and remind patients about doses, opening opportunities for tech companies and pharmaceutical partnerships.

Regional Insights

In the United States, the asthma therapeutics market is driven by a high prevalence of asthma alongside strong healthcare infrastructure. Patent expirations, novel biologics, and personalized medicine drive research and innovation in the region. Various organizations in the region continue to find a cure for and control asthma, food allergies, nasal allergies, and other allergic diseases. South America shows a growing need for asthma therapeutics, largely due to increasing awareness of respiratory diseases and improving healthcare facilities. Europe represents a substantial market for asthma therapeutics, supported by high awareness levels, established healthcare systems, and favorable reimbursement policies. The presence of several key market players and a strong emphasis on research and development activities are notable factors. Western European countries, including Germany, France, Switzerland, the United Kingdom, France, and Italy, hold a major market share, while Eastern European countries exhibit potential for growth due to improving healthcare infrastructure and rising asthma prevalence. The market in the Middle East is advancing with the development of healthcare infrastructure and increasing private sector investment. In contrast, Africa faces challenges such as limited healthcare services, low awareness, and inadequate access to treatment, which hinder market growth. However, certain countries, including South Africa, are making strides in asthma care, which can positively influence regional market development. In APAC, China's asthma therapeutic market is developing rapidly due to the growing middle class and enhanced healthcare reforms. In Japan, patients have access to several state-of-the-art treatments, reflecting the country's advanced healthcare system and high patient awareness. Japan's pharmaceutical sector is highly innovative, with a robust pipeline of new drugs and consistent investment in R&D. India's asthma treatment market is characterized by a need for affordable medications and increased education on asthma management. The high population, coupled with pollution issues, contributes to a growing prevalence of asthma. Government programs and non-profit initiatives aim to enhance asthma care accessibility and affordability throughout the subcontinent.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Asthma Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing Incidences of Asthma and Other Respiratory Diseases
    • Recent Improvements in Allergy Detection and Diagnostic Technologies
    • Extensive Demand for Monoclonal Antibodies
    • Market Restraints
      • Limitation and Side Effects of Asthma Therapeutic Devices
      • Market Opportunities
        • Development of Combination Therapeutics for The Treatment
        • Extensive Research and Development (R&D) Efforts for Asthma Treatment
        • Market Challenges
          • Limited Therapeutics Reach in Remote & Rural Areas
          • Market Segmentation Analysis
            • Product: Rising demand for metered dose inhalers for the treatment of asthma
            • Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
            • Route of administration: Expanding adoption of inhaled asthma medication for fast relief
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Asthma Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Asthma Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
              
              GlaxoSmithKline PLC has announced the acquisition of Aiolos Bio Inc. with an investment of USD 1.4 billion. This acquisition aims to enhance GSK's foothold in the asthma treatment market as this deal gives GSK access to AIO-001, a cutting-edge asthma therapy by Aiolos Bio.
              
              Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
              
              Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. announced an exclusive license agreement to develop a potential novel antibody-based therapy for treating Atopic Dermatitis and Asthma. BD9 is novel for its dual-action mechanism that inhibits both TSLP and IL-13, offering a more comprehensive treatment option over current single-target therapies. This collaboration is a strategic move complementing Teva's 'Pivot to Growth' strategy, which was unveiled in May 2023 and focuses on stoking innovation through partnerships and enhancing Teva's early-stage pipeline.
              
              Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment
              
              Hormosan Pharma GmbH, a fully owned subsidiary of Lupin Limited, announced the launch of Luforbec 100/6, a fixed blend in a pressurized metered dose inhaler (pMDI) for the remedy of adult chronic obstructive pulmonary disease (COPD) and asthma in Germany.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Asthma Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.p.A., Cipla Limited, F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Koninklijke Philips N.V., Lupin Limited, Medtronic PLC, Merck & Co, Inc., Merxin Ltd., Novartis AG, Parekhplast India Limited, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Shenzhen Aeon Technology Co., Ltd., Softhale NV by invoX Pharma Limited, Sun Pharmaceutical Industries Limited, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Trudell Medical Limited, Viatris Inc., and Wellinks, Inc..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Product
              • Inhalers
                • Dry Powder Inhalers
                • Metered-Dose Inhalers
                • Soft Mist Inhalers
                • Nebulizers
                • Drug Class
                  • Anti-Inflammatory
                  • Bronchodilators
                  • Combination Therapy
                  • Route of administration
                    • Inhaled
                    • Oral
                    • Region
                      • Americas
                        • Argentina
                        • Brazil
                        • Canada
                        • Mexico
                        • United States
                          • California
                          • Florida
                          • Illinois
                          • New York
                          • Ohio
                          • Pennsylvania
                          • Texas
                          • Asia-Pacific
                            • Australia
                            • China
                            • India
                            • Indonesia
                            • Japan
                            • Malaysia
                            • Philippines
                            • Singapore
                            • South Korea
                            • Taiwan
                            • Thailand
                            • Vietnam
                            • Europe, Middle East & Africa
                              • Denmark
                              • Egypt
                              • Finland
                              • France
                              • Germany
                              • Israel
                              • Italy
                              • Netherlands
                              • Nigeria
                              • Norway
                              • Poland
                              • Qatar
                              • Russia
                              • Saudi Arabia
                              • South Africa
                              • Spain
                              • Sweden
                              • Switzerland
                              • Turkey
                              • United Arab Emirates
                              • United Kingdom
                              
                              
                              Please Note: PDF & Excel + Online Access - 1 Year